Stryker Corp Advances Medical Technologies with InThrill Thrombectomy System Launch

Stryker Corp has launched the InThrill Thrombectomy System, a medical technology developed by its subsidiary Inari Medical. The system is designed to address arteriovenous access and small vessel thrombus cases.

Key Features of the InThrill Thrombectomy System:

• Designed to improve thrombectomy procedures
• Addresses arteriovenous access and small vessel thrombus cases

Analyst Outlook

Analysts remain optimistic about Stryker Corp’s prospects. TD Cowen maintains a Buy rating with a price target of $435.

Company Valuation

Stryker Corp’s valuation has reached levels not seen since 2020 and 1993, driven by growth in its orthopedics business, particularly in robot-assisted surgeries.

Q2 Earnings Expectations

Despite potential tariff overhang, Stryker Corp’s Q2 earnings are expected to reflect strong growth.